Press Releases

Date Title and Summary View
Toggle Summary MediWound Provides Progress Update on Its EscharEx Clinical Development Program
Phase 2 Adaptive Design Study Sample Size Reduced to 120 Patients Interim Assessment Expected in Mid-2021 and Completion of Enrollment by Year-End 2021 Protocol Submitted to FDA for Pharmacology Clinical Study with Data Expected in Second Half 2021 YAVNE, Israel , Jan.
View HTML
Toggle Summary MediWound to Participate in Upcoming Investor Conferences in January
YAVNE, Israel , Jan. 05, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that it will participate in the forthcoming LifeSci Partners 10 th
View HTML
Toggle Summary Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent
Data to be Published in a Peer-Reviewed Journal in First Half 2021 YAVNE, Israel , Dec. 21, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced
View HTML
Toggle Summary MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group
YAVNE, Israel , Dec. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid ® global presence and entered
View HTML
Toggle Summary MediWound Reports Third Quarter 2020 Financial Results
Total Third Quarter R evenues of $6.6   Million Increased 29 % Y ear-over- Y ear Assigned PDUFA Goal Date of June 29, 2021   for NexoBrid BLA YAVNE, Israel , Nov. 10, 2020 (GLOBE NEWSWIRE) --  MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies
View HTML
Toggle Summary MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020
YAVNE, Israel, Nov. 02, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the third
View HTML
Toggle Summary MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
Top-line Data is Expected in the Second Half of 2021 YAVNE, Israel , Oct. 28, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has
View HTML
Toggle Summary MediWound Studying the Effect of EscharEx on Biofilm Burden
Bromelain Degradation of Biofilms Could Provide Clinically Meaningful Benefits in Wound Healing YAVNE, Israel , Oct. 14, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) ("MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe
View HTML
Toggle Summary MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
YAVNE, Israel , Sept. 16, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “MediWound”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the U.S.
View HTML
Toggle Summary MediWound to Present at Upcoming Investor Conferences in September
YAVNE, Israel , Sept. 03, 2020 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that Sharon Malka , MediWound’s Chief Executive
View HTML